Advanced Biomed

Business model and assets are in flux. The original potential moat (biochip know‑how, devices like A+Pre, AC‑1000, A+CellScan, A+SCDrop, and the A+PerfusC 3D culture platform) has not translated into commercial approvals or sales, and the Taiwan R&D subsidiary that housed these efforts is being sold.

The company is pivoting toward AI (Acellent HK), where it has no visible scale, network, or entrenched customer base. Component view and weights: Intangibles/brand 15/100 (limited recognition; shifting portfolio). Switching costs 5/100 (no installed base). Network effects 5/100 (none evident). Cost advantage 10/100 (no scale).

Efficient scale 10/100 (target markets are crowded rather than capacity‑constrained). Weighted result is low because the more durable moats (switching costs, network effects) are absent and the original IP is leaving the perimeter.